BIO-key heads into its fiscal third-quarter report with a promise it has now made four quarters running: the second half of the year is when the business finally tips toward profitability. Last quarter, management blamed a revenue shortfall on a large hardware order that slid out of the June period and into the back half. The September quarter is the first real chance to see whether that order shows up, and whether the much-repeated profitability goal is closer to reality or simply drifting forward again.
The Street is asking a lot on the top line. Consensus calls for revenue of about $2.4 million, up roughly 55% from $1.6 million a year ago. That would comfortably exceed both the $1.9 million reported last quarter and the $2.1 million posted in the first quarter, making it the strongest quarter in the recent run. On the bottom line, analysts expect a loss of $0.35 per share, narrower than last quarter's $0.56 loss but wider than the $0.15 loss a year earlier, a comparison likely muddied by the 1-for-10 reverse split and the share count changes that came with recent financing. The company has not issued formal numeric guidance, so the revenue estimate effectively bakes in the delayed hardware deal plus contributions from newer wins. Notably, the loss estimate suggests analysts are not penciling in the breakeven quarter management has been pointing toward.
The mix of that revenue matters as much as the total. Gross margin hit a record 87% last quarter, helped by license revenue climbing 53% and by selling previously reserved inventory at essentially full margin. A big hardware shipment would help revenue but could pull blended margin back toward the low 80s, so a modest margin retreat alongside a revenue jump would not necessarily signal weakness. What would be concerning is a quarter where hardware fails to recover from last quarter's 19% decline and services keep shrinking, since that would suggest the slippage explanation, which has surfaced repeatedly over the past year, reflects something more persistent than calendar timing. Management also flagged August holidays in EMEA as a seasonal drag, which gives it a ready explanation if results come in light.
The international pipeline is where the longer-term story either gains traction or stalls. Last quarter brought a cluster of genuinely new names: the sole-source Central Bank of Jordan mandate, which management likened to a South African bank relationship worth more than $1 million in annual recurring revenue, plus the Maktabi Tech education partnership across Saudi Arabia, Jordan and the UAE, a Portuguese national security agency and a U.S. credit union. Early license revenue or deployment milestones from Jordan in particular would go a long way toward validating the narrative. Updates on the PortalGuard 7.0 rollout and any concrete progress on the agentic AI identity governance pitch would help, though management itself conceded that opportunity is early.
The market has not been patient. Shares have fallen about 24% since the last report, trailing the S&P 500 by nearly 19 percentage points, with pressure from a warrant holder quickly moving shares out of abeyance after the $2.5 million raise. At $2.38, the stock sits below its 200-day moving average of $2.61 and in the lower part of its post-earnings range of $1.55 to $4.66, well beneath the prior quarter's $3.54 to $6.10 band. Sentiment, however, has softened from heavily bearish to only modestly so, implying the crowd has partly priced in the disappointments. Cash burn will also be scrutinized against the pro forma cash position of more than $4.5 million.
Ultimately, this report comes down to whether the slipped hardware order converts. If it lands and revenue reaches the $2.4 million area with licenses holding up, the second-half profitability story stays credible for the December quarter. If it slips again, management's timing explanations will start to look like a pattern rather than an exception.